16 May 2012: Apposition III Results

14 May 2012: STENTYS expands its product offerings

02 May 2012: Revenues for the first quarter of 2012

07 March 2012: 2011 Financial Results

08 February 2012: Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

01 February 2012: STENTYS concludes clinical trial ahead of plan

26 January 2012: STENTYS raises €8.3m in capital

25 January 2012: Private placement

16 January 2012: Full-Year Sales for 2011

13 December 2011: Financial agenda for 2012

09 November 2011: Revenues for the 3rd quarter 2011

08 November 2011: Outstanding interim results of STENTYS international clinical study APPOSITION III

12 October 2011: STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks

21 September 2011: STENTYS completes enrollment of APPOSITION III study

15 September 2011: Over 1000 patients have benefited from STENTYS Self-Apposing technology

31 August 2011: 2011 Half-Year results

26 July 2011: Revenues for the 1st half of 2011

20 June 2011: Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board

08 June 2011: STENTYS recruits Country managers for France and Italy

16 May 2011: Stenting in STEMI: Does Size Matter?

11 May 2011: Significant revenue increase in the 1st quarter of 2011

02 May 2011: STENTYS enrolls first 250 patients within the framework of its Apposition III international study

24 March 2011: FY 2010 financial results

17 March 2011: STENTYS expands operations into four additional European countries

23 February 2011: Increased reimbursement of STENTYS drug-eluting stent in Germany

08 February 2011: Full year 2010 revenues

Sales grew by +66.7% in the 4th quarter of 2010 vs. the 3rd quarter of 2010.

24 January 2011: Financial events: agenda 2011

09 December 2010: Launch of APPOSITION III - 50 patients already enrolled

STENTYS announces the start of APPOSITION III, a key milestone of the company's development plan and a confirmation that STENTYS is perfectly in line with the road map that was presented during the IPO. 

23 November 2010: STENTYS appoints Mr Michel Darnaud to its Board of Directors

19 November 2010: Definitive amount of capital increase and Communication regarding the details of stabilisation operations

15 November 2010: Steady Growth in Q3 2010

Increasing interest in STENTYS' innovative stents among European cardiologists following positive results of the APPOSITION II study.

22 October 2010: Successful IPO of STENTYS on NYSE Euronext Paris

The Public Offering was more than twice oversubscribed and the Global Placement 1.1 time

- Offering Price: €12.00  per share

- Amount of the offer:  €22.7 million, before the exercise of the over-allotment option

- Trading to begin on October 25th, 2010 in the form of promises of shares
 

12 October 2010: STENTYS launches its initial public offering on NYSE Euronext

09 September 2010: First step towards Initial Public Offering on the Paris NYSE Euronext market

STENTYS files its « Document de Base » with the French Autorité des marchés financiers